Please be advised that the Vision 3 Release DLM 820 reinstates the Login Retries and Lock out user when login failed “retries” times options available from Management Tools – Security - Security Settings
Latest News
Please be aware, the Prescribing Safety Audit Indicator PS015, in Informatica’s Audit+, is looking for a Read Code of 422..00 Full Blood Count in the patient’s record. Some Vision 3 practices do not automatically enter this clinical term into the patient record when test results automatically file from Mail Manager.
If your practice receives data from Vision Anywhere as part of a federation, cluster or shared service, it is important you do not inactivate the Dr Federated User staff member in Vision 3 Control Panel
Opening Tagged Image Format (.TIF) Files from 3rd August 2022 – England Only Due to the way TPP practices send GP2GP data, from the 4rd August 2022 when you select to open an attachment from Vision 3, if it is a .TIF file it automatically opens in Windows Photo Viewer.
Please be advised that the NHS initiative hosted by The Royal Marsden NHS Foundation Trust known as Co-ordinate My Care (CMC) is being decommissioned
With it being Registrar time again, please note the following useful guides to assist you in adding and inactivating clinical staff
To support the change in legislation from April 6th 2022, the MED3 (Statement of Fitness for Work) created by both Vision 3 and Vision Anywhere has been updated
We are aware that our Help Centres across all products are currently unavailable. We are working to rectify this issue as soon as possible and will notify you via this feed once they are back on line. We are sorry for any inconvenience caused.
In response to the latest vaccination programme changes, the following updates have been made to Vision 3
Oxybutynin 3.9mg/24hours transdermal patches was marked as discontinued in dm+d in August 2021. This means that once the September Gemscript update was installed, you could no longer prescribe it as an NHS prescription in Vision 3 or Vision Anywhere.